[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338114-105":59,"doc-detail-338114-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","olaparib-plus-trastuzumab-in-her2-positive-advanced-breast-cancer-patients-with-germline-brca12-mutations-the-ophelia-phase-2-study","Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study","","Purpose: evaluate the efficacy and safety of olaparib plus trastuzumab in HER2-positive advanced breast cancer (ABC) patients with germline BRCA mutations (gBRCAm). Methods: OPHELIA was a single-arm, open-label phase 2 trial enrolling adults ≥18 with HER2-positive ABC and germline deleterious BRCA1/BRCA2 mutations after ≥1 prior systemic regimen; treatment continued until progression, unacceptable toxicity, or withdrawal. Primary endpoint was investigator-assessed clinical benefit rate for ≥24 weeks; secondary endpoints included ORR and safety. Results: 5 patients were enrolled due to slow accrual; four achieved clinical benefit and the primary endpoint was met; ORR was 60%. Safety: TEAEs occurred in 80% with mostly grade 1–2; no treatment-related deaths and no new safety signals. Conclusion: the combination may be effective and safe for pre-treated HER2-positive gBRCAm ABC; further study is warranted.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/olaparib-plus-trastuzumab-in-her2-positive-advanced-breast-cancer-patients-with-germline-brca12-mutations-the-ophelia-phase-2-study/338114/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/olaparib-plus-trastuzumab-in-her2-positive-advanced-breast-cancer-patients-with-germline-brca12-mutations-the-ophelia-phase-2-study/338114.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary goal of the OPHELIA phase 2 study?","Question",{"text":112,"@type":113},"To evaluate the efficacy and safety of combining olaparib with trastuzumab in patients with HER2-positive advanced breast cancer and germline BRCA1/2 mutations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study designed and who was eligible?",{"text":117,"@type":113},"OPHELIA was a single-arm, open-label phase 2 trial. Eligible patients were adults (≥18) with HER2-positive advanced breast cancer and germline deleterious BRCA1 or BRCA2 mutations after at least one prior systemic regimen for advanced disease.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key results for efficacy and safety?",{"text":121,"@type":113},"Four of five treated patients achieved clinical benefit and the primary endpoint was met. The ORR was 60% with one complete response. Treatment-related TEAEs occurred in 80% of patients, mostly grade 1–2, with no treatment-related deaths and no new safety signals.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338114,1790195396,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","The Breast 77 (2024) 103780  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \nOlaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study  \nJos´e Enrique Al´es-Martínez a, * , Judith Balma˜nab , Pedro S´anchez-Rovira c ,  \nFrancisco Javier Salvador Bofill d , Jose ´Angel García S´aenze , Isabel Pimentel b , Serafín Morales f, María Fern´andez-Abad g, h , Ainhara Lahuerta Martínezi , Neus Ferrer j , Pilar Zamora k, Bego˜na Bermejo l , Tamara Díaz-Redondom , María Helena L´opez-Ceballosn , María Gal´an o , Jhudit P´erez-Escuredop , Laura Calabuigp , Miguel Sampayop , Jos´e Manuel P´erez-Garcia p, q, Javier Cort´es p, q, r, u , Antonio Llombart-Cussac p, s, t  \na Hospital Nuestra Sra. De Sonsoles, ´Avila, Spain b Hospital Universitari Vall D’Hebron, Barcelona, Spain c Hospital Universitario de Ja´en, Ja´en, Spain d Hospital Universitario Virgen del Rocío, Sevilla, Spain e Hospital Clínico San Carlos, Madrid, Spain  \nf Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain g Hospital Universitario Ram´on y Cajal, Madrid, Spain h Universidad de Alcala´ de Henares, Madrid, Spain i Onkologikoa, Gipuzkoa, Spain  \nj Hospital Universitari Son Espases, Illes Balears, Spain k Hospital Universitario de La Paz, Madrid, Spain l Hospital Clínico Universitario de Valencia, Valencia, Spain  \nm Unidad de Gesti´on Clínica Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria de M´alaga, M´alaga, Spain n Hospital San Pedro de Alc´antara, C´aceres, Spain  \no Hospital Son Lla`tzer, Palma de Mallorca, Spain  \np Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA), Sao Paulo, Brazil q International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain  \nr Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain  \ns Hospital Arnau de Vilanova, FISABIO, Valencia, Spain t Universidad Cat´olica de Valencia, Valencia, Spain u IOB Madrid, Hospital Beata María Ana, Madrid, Spain  \nA R T I C L E I N F O  \nKeywords:  \nHER2-Positive Advanced breast cancer BRCA mutation Olaparib  \nTrastuzumab  \nA B S T R A C T  \nPurpose: To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal BRCA mutations (gBRCAm).  \nMethods: OPHELIA (NCT03931551) was a single-arm, open-label, phase 2 clinical trial. Patients aged ≥18 years diagnosed with HER2-positive ABC with germinal deleterious mutations in BRCA1 orBRCA2 who had received at least one prior systemic regimen for advanced disease were enrolled. Patients received olaparib plus trastuzumab until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was investigatorassessed clinical benefit rate for at least 24 weeks as per RECIST v.1.1. Key secondary endpoints included overall response rate (ORR) and safety profile.  \nResults: A total of 68 pre-treated HER2-positive ABC patients were screened. Due to slow accrual the trial was stopped after enrolling 5 patients instead of the planned sample size of 20. Four patients achieved clinical benefit (80.0 %, 95 % CI; 28.4–99.5, p \u003C 0.001) and the primary endpoint was met. The ORR was 60.0 %(95 % CI; 14.7–94.7), including one complete response. Four (80.0 %) patients experienced at least one treatment-related treatment-emergent adverse event (TEAE). Most TEAEs were grade 1 or 2. There were no treatment-related deaths and no new safety signals were identified.  \n* Corresponding author.  \nE-mail address: [jealesm@seom.org](jealesm@seom.org) (J.E. Al´es-Martínez).  \n[https://doi.org/10.1016/j.breast.2024.103780](https://doi.org/10.1016/j.breast.2024.103780)  \nRe","cbCaifAXZsdqqDcQ","https://ap.wps.com/l/cbCaifAXZsdqqDcQ","pdf",594712,"English","# Introduction\n## Clinical outcomes and endpoints\n## Safety assessment and adverse events\n## Conclusions and implications","[{\"question\":\"What is the primary goal of the OPHELIA phase 2 study?\",\"answer\":\"To evaluate the efficacy and safety of combining olaparib with trastuzumab in patients with HER2-positive advanced breast cancer and germline BRCA1/2 mutations.\"},{\"question\":\"How was the study designed and who was eligible?\",\"answer\":\"OPHELIA was a single-arm, open-label phase 2 trial. Eligible patients were adults (≥18) with HER2-positive advanced breast cancer and germline deleterious BRCA1 or BRCA2 mutations after at least one prior systemic regimen for advanced disease.\"},{\"question\":\"What were the key results for efficacy and safety?\",\"answer\":\"Four of five treated patients achieved clinical benefit and the primary endpoint was met. The ORR was 60% with one complete response. Treatment-related TEAEs occurred in 80% of patients, mostly grade 1–2, with no treatment-related deaths and no new safety signals.\"}]","Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study | PDF",1790021987,13,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f8f0cb232f86f2daf5681c885d751f5.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79b840b600ce45bc4b17e411aa3d1fdc.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f88555603f029a3fddeb4c01d2d76a55.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/881375c92598bfeed1648bcb9fe25027.webp",980,1306]